Omnipod® 5 For Pediatrics
Omnipod® 5—The Best of Both Worlds for Kids and Teens
We firmly believe in simplifying life with diabetes and simplifying diabetes care. Now your T1D patients don't have to choose between the simplicity of a tubeless device and the effectiveness of an automated insulin delivery system (AID). See a message from one of our Podders and the impact that Omnipod 5 has had on her and her family’s lives.
* For a list of compatible smartphone devices visit omnipod.com/compatibility.
- Omnipod 5 reduced time in hypoglycemia overall and overnight for children aged 2-5.9 years old1
- Indicated for type 1 diabetes for ages 2+
- Freedom from tubes and from daily injections
- Wireless data uploads to help review your patients’ data
- Program a bolus delivery via the Controller or compatible smartphone*, so caregivers don’t have to interrupt play
- An on-body experience with a waterproof Pod2 so whether kids are swimming, splashing, or showering, Omnipod 5 keeps working
Improved Clinical Results
A clinical study for children 2-5.9 years old showed:
LESS TIME
IN HYPOGLYCEMIA
With a 1.28% reduction overnight and a 0.97% reduction overall.1
MORE TIME IN RANGE
With 81% time in range overnight and 68% overall.1
LOWER A1C
After 3 months of use, 54% had an HbA1c under 7%.1
Omnipod 5 Adapts to Kids’ Varying Insulin Needs as They Grow
Omnipod 5 automatically increases, decreases, or pauses insulin delivery, every five minutes, to meet your patients’ insulin needs.
How it works:
- Predicts glucose 60 minutes into the future
- Adjusts insulin delivery proactively using the Glucose Target, which is customizable from 110 mg/dL to 150 mg/dL in 10 mg/dL increments. Different targets can be set at different times if desired
- Delivers insulin doses every 5 minutes (as needed) to help protect against hyperglycemia and hypoglycemia1,3
- On-body AID technology that goes wherever your patients go. With Omnipod 5, your patients don’t need to disconnect from automated insulin delivery for daily activities4
Want more information on how Omnipod 5 works? Watch the video below.
Still Have Questions?
Watch this video for more information and answers to some of the most common questions providers have when starting their patients on Omnipod 5.
#1 Most Requested Pump by US Patients5
Over 90% insured patients nationwide are covered for the Omnipod 56
Over 47,000 pharmacies have dispensed Omnipod 57
Majority of Omnipod 5 users pay $30 or less per month8
Prescribe Omnipod the Same Way as Prescribing Insulin.
For more details on coverage, use our Coverage Lookup Tool
Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information.
1. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05. Mean time 70-180mg/dL (12AM-6AM) as measured by CGM: ST = 58.2%, 3-mo Omnipod 5 =81.0%, P<0.0001. Mean time in range (70-180mg/dL) in very young children (2 - 5.9 yrs) as measured by CGM: ST = 57.2%, 3-mo Omnipod 5 = 68.1%, P<0.05. Mean time in hypoglycemic range (<70 mg/dL) as measured by CGM: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) (3.43% vs. 2.46%, P=0.0204). Mean time <70 mg/dL (12AM-6AM) as measured by CGM in very young children (2 - 5.9 yrs), ST vs. 3-mo Omnipod 5: 3.4% vs. 2.1%, P=0.0185. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001.
2. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.
3. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Mean time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, P<0.0001; 2.2% vs. 1.8%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
4. Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines.
5. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25
6. Reflects coverage for Omnipod 5 DexG7G6 Intro Kit and Omnipod 5 DexG7G6 Pods in commercial channel only. Majority defined as >50%. Source: Managed Markets Insights & Technology, LLC. Data as of April 2025.
7. Reflects total Omnipod 5 unique pharmacy dispensing count. Source: Insulet Data on File as of Q4 2024
8. Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library
1. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05. Mean time 70-180mg/dL (12AM-6AM) as measured by CGM: ST = 58.2%, 3-mo Omnipod 5 =81.0%, P<0.0001. Mean time in range (70-180mg/dL) in very young children (2 - 5.9 yrs) as measured by CGM: ST = 57.2%, 3-mo Omnipod 5 = 68.1%, P<0.05. Mean time in hypoglycemic range (<70 mg/dL) as measured by CGM: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) (3.43% vs. 2.46%, P=0.0204). Mean time <70 mg/dL (12AM-6AM) as measured by CGM in very young children (2 - 5.9 yrs), ST vs. 3-mo Omnipod 5: 3.4% vs. 2.1%, P=0.0185. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001.
2. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.
3. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Mean time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, P<0.0001; 2.2% vs. 1.8%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
4. Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines.
5. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25
6. Reflects coverage for Omnipod 5 DexG7G6 Intro Kit and Omnipod 5 DexG7G6 Pods in commercial channel only. Majority defined as >50%. Source: Managed Markets Insights & Technology, LLC. Data as of April 2025.
7. Reflects total Omnipod 5 unique pharmacy dispensing count. Source: Insulet Data on File as of Q4 2024
8. Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library
INS-OHS-06-2023-00147 v2.0